Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Schumer Preparing Strong Public Plan Option
Sen. Charles Schumer, D-N.Y., a member of the key Senate Finance Committee and advocate for a government-run health insurance plan, said yesterday he would abandon all other possible compromises in favor of immediately creating a public plan that "would operate on "a level playing field" with private insurers," CongressDaily reports. Other proposals have included a plan that would establish health insurance co-ops with government seed money or "trigger" the creation of a public plan only if private insurers fail to meet certain targets for containing costs and improving access.
generic viagra online
National Organization for Rare Disorders (NORD) Sponsors Rare Disease Summit
A shortage of new pharmaceutical products in the pipeline-combined with new scientific tools-has created a climate of opportunity for the rare disease community, a senior Food and Drug Administration (FDA) official said at a conference hosted by the National Organization for Rare Disorders (NORD).
News of the day
Tube Feeding Error: Fatal Medical Mistakes
The American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.), whose mission is to improve patient care by advancing the science and practice of nutrition support therapy, is saddened by the recent death of an infant in Madrid, Spain, who died when formula was given to him through an IV catheter and not through a feeding tube in his stomach.
Health Insurance

ChemoCentryx To Present At The 9th World Congress On Inflammation In Tokyo, Japan

ChemoCentryx, Inc. announced that Thomas J. Schall, Ph.D., ChemoCentryx"s President and Chief Executive Officer, will give a keynote lecture at The 9th World Congress on Inflammation in Tokyo, Japan. Dr. Schall"s lecture titled, "Treating Inflammation by Inhibition of Chemokine Receptors: Practical Requirements and Efficacy of CCR9 Antagonism in Inflammatory Bowel Disease" will be given on Thursday, July 9, 2009 at 9:00 am local time. "It is a privilege to have been invited to speak at this prestigious gathering of thought leaders involved in the search for innovative treatments in inflammatory disease," said Thomas J. Schall, Ph.D., ChemoCentryx"s President and Chief Executive Officer. "With recent regulatory approvals and clinical trial successes of chemokine-based therapeutics, this underscores the enthusiasm and promise of developing drugs that selectively inhibit specific chemokine and chemoattractant receptors in the treatment of inflammatory diseases." About ChemoCentryx ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx"s lead compound, Traficet-EN, a specific CCR9 antagonist, is in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn"s disease. CCX025, also a CCR9 antagonist, is in a Phase I clinical trial. Additional clinical programs include the development of CCX140, which targets the CCR2 receptor, currently in a Phase I clinical trial and intended for subsequent development to treat diseases such as Type 2 diabetes, multiple sclerosis and vascular restenosis, and CCX354, a CCR1 antagonist in a Phase I clinical trial, being developed for inflammatory diseases such as rheumatoid arthritis. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. ChemoCentryx, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009